A Clinical Study of GC012F Injection in High-risk, Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
| Title | A Clinical Study of GC012F Injection in High-risk, Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma |
|---|---|
| Description | This study was a single-arm, single-center, open-label clinical study to evaluate the safety and efficacy of GC012F in high-risk, transplantation-eligible NDMM patients. The study was planned to include 20 evaluable subjects. A total of two cycles of induction therapy (bortezomib-based three-drug regimen, with details determined by the investigator on the basis of the patient) were selectively administered before or after collection in eligible subjects. Participants will then receive a single GC012F infusion, with response assessments at 1 month, 3 months, and every 3 months thereafter for 2 years until the end of the trial (each response assessment will require MRD testing). |
| Organism | Homo sapiens |
| Data Type | Genetic Biomarkers |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA023219 |
| Release Date | 2024-01-27 |
| Submitter | mingyue xiang (mingyue.xiang@gracellbio.com) |
| Organization | Gracell Biotechnologies Inc |
| Submission Date | 2024-01-26 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX005753-01 | NDMM IIT | 1 | Genetic Biomarkers | 57.9 KB | xlsx | 0 | Controlled |